Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701335 | 1.00 | CA2 (0.41) | CA2SOAT1MEN1FAAHKMT2A | |
| SCHEMBL4013191 | 0.85 | ALOX15 (0.33) | KMT2A | |
| SCHEMBL27033144 | 0.83 | TSHR (0.50) | MEN1KMT2ALMNA | |
| SCHEMBL11477514 | 0.76 | SOAT1 (0.42) | CA2SOAT1MEN1FAAHKMT2A | |
| SCHEMBL7352870 | 0.76 | CA2 (0.41) | CA2MEN1FAAHKMT2AKDM4E | |
| SCHEMBL2810385 | 0.76 | SOAT1 (0.42) | CA2SOAT1MEN1FAAHKMT2A | |
| SCHEMBL7765920 | 0.76 | SOAT1 (0.42) | CA2SOAT1MEN1FAAHKMT2A | |
| SCHEMBL11456167 | 0.76 | SOAT1 (0.42) | CA2SOAT1MEN1FAAHKMT2A | |
| SCHEMBL3359743 | 0.75 | APEX1 (0.42) | CA2SOAT1MEN1FAAHKMT2A | |
| SCHEMBL3359740 | 0.75 | KMT2A (0.40) | SOAT1MEN1FAAHKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CA2 743/4885SOAT1 4606/4885MEN1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.